BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022
October 27, 2022 07:00 ET
|
BioXcel Therapeutics
NEW HAVEN, Conn., Oct. 27, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative...
BioXcel Therapeutics to Host IGALMI™ Commercial Day on October 18, 2022
October 05, 2022 07:00 ET
|
BioXcel Therapeutics
NEW HAVEN, Conn., Oct. 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative...
BioXcel Therapeutics to Participate at the H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022 07:00 ET
|
BioXcel Therapeutics
NEW HAVEN, Conn., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative...
BioXcel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Operational Highlights
August 09, 2022 07:00 ET
|
BioXcel Therapeutics
Commercially launched IGALMI™ (dexmedetomidine) sublingual film for the acute treatment of agitation in bipolar I or II disorder and schizophrenia in adult patients SERENITY III pivotal...
BioXcel Therapeutics to Participate at the Canaccord Genuity 42nd Annual Growth Conference
August 03, 2022 07:00 ET
|
BioXcel Therapeutics
NEW HAVEN, Conn., Aug. 03, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop...
BioXcel Therapeutics Announces NIH NIDA Grant to Columbia University to Support Further Studies of BXCL501 (Sublingual Dexmedetomidine) for Treating Opioid Withdrawal
August 01, 2022 07:00 ET
|
BioXcel Therapeutics
Multi-year-funded award to support a 160-patient, randomized-controlled study in patients undergoing opioid withdrawal treatmentOver 142 million opioid prescriptions dispensed in the U.S. in 20201More...
BioXcel Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
July 26, 2022 07:00 ET
|
BioXcel Therapeutics
NEW HAVEN, Conn., July 26, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop...
BioXcel Therapeutics Appoints Michael P. Miller to Board of Directors
July 05, 2022 07:00 ET
|
BioXcel Therapeutics
NEW HAVEN, Conn., July 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop...
BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences
June 07, 2022 07:00 ET
|
BioXcel Therapeutics
NEW HAVEN, Conn., June 07, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop...
BioXcel Therapeutics Announces Updated Presentation Time at H.C. Wainwright Global Investment Conference
May 20, 2022 07:00 ET
|
BioXcel Therapeutics
NEW HAVEN, Conn., May 20, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop...